Table 3

Risk-Based Estimate of Human Fungal Disease Burden, China

Ling-Hong Zhou¹, Ying-Kui Jiang¹, Ruo-Yu Li, Li-Ping Huang, Ching-Wan Yip, David W. Denning², and Li-Ping Zhu²

Author affiliations: Huashan Hospital, Shanghai, China; and Fudan University, Shanghai (L.-H. Zhou, Y.-K. Jiang, L.-P. Huang, C.-W. Yip, L.-P. Zhu); Peking University First Hospital, Beijing, China (R.-Y. Li); Peking University, Beijing (R.-Y. Li); National Clinical Research Center for Skin and Immune Diseases, Beijing (R.-Y. Li); Wythenshawe Hospital, Manchester, UK (D.W. Denning); University of Manchester, Manchester (D.W. Denning); Global Action Fund for Fungal Infections, Geneva, Switzerland (D.W. Denning)

Main Article

Summary of fungal infection burden in China according to major risk factors*

Infection	No. infections per underlying disorder per year					Total no. cases	Rate/100,000 population
Infection	None	HIV/AIDS	Respiratory	Cancer	ICU	Total no. cases	Rate/100,000 population
Candidemia	NE	NE	NE	65,609	16,402	82,011	5.72
Candida peritonitis
ICU + surgery	NE	NE	NE	NE	8,939	8,939	0.62
CAPD	738	NE	NE	NE	NE	738	0.05
Oral candidiasis	NE	74,258	NE	NE	NE	74,258	5.18
Esophageal candidiasis	NE	49,204	NE	NE	NE	49,204	3.43
Recurrent Candida vaginitis	29,082,000	NE	NE	NE	NE	29,082,000	4,056.68†
IA	NE	1,040	1,145,908	31,800	NE	1,178,748	82.21
CPA	NE	NE	488,716	NE	NE	488,716	34.09
ABPA	NE	NE	1,237,797	NE	NE	1,237,797	86.33
SAFS	NE	NE	1,633,892	NE	NE	1,633,892	113.96
CM	26,249	13,086	NE	26,172	NE	65,607	4.57
PCP	NE	18,482	NE	9,241	NE	27,723	1.93
Talaromycosis	NE	4,951	NE	NE	NE	4,951	0.35
Mucormycosis	2,868	NE	NE	NE	NE	2,868	0.20
Fungal keratitis	100,365	NE	NE	NE	NE	100,365	7.00
Onychomycosis	37,278,384	NE	NE	NE	NE	37,278,384	2,600.00
Total burden	66,490,604	161,021	4,506,313	132,822	25,341	71,316,101	7,002.32

*ABPA, allergic bronchopulmonary aspergillosis; ART, antiretroviral therapy; CAPD, continuous ambulatory peritoneal dialysis; CM, cryptococcal meningitis; CPA, chronic pulmonary aspergillosis; IA, invasive aspergillosis; ICU, intensive care unit; NE, no estimation could be made because of the lack of data; PCP, pneumocystis pneumonia; SAFS, severe asthma with fungal sensitization.
†Female population only.

Main Article

¹These authors contributed equally to this article.

²These authors contributed equally to this article.

Page created: May 26, 2020

Page updated: August 18, 2020

Page reviewed: August 18, 2020

The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.